Non-Down-syndrome-related acute megakaryoblastic leukemia in children: a clinical analysis of 17 cases.
10.7499/j.issn.1008-8830.2502082
- Author:
Ding-Ding CUI
1
;
Ye-Qing TAO
1
;
Xiao-Pei JIA
1
;
An-Na LIAN
1
;
Qiu-Xia FAN
;
Dao WANG
1
;
Xue-Ju XU
1
;
Guang-Yao SHENG
1
;
Chun-Mei WANG
1
Author Information
1. Department of Pediatric Hematology and Oncology, Children's Hospital of First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
- Publication Type:Journal Article
- Keywords:
Acute megakaryoblastic leukemia;
Child;
Clinical feature;
Prognosis
- MeSH:
Humans;
Male;
Female;
Leukemia, Megakaryoblastic, Acute/etiology*;
Child, Preschool;
Infant;
Child;
Retrospective Studies;
Prognosis;
Down Syndrome/complications*
- From:
Chinese Journal of Contemporary Pediatrics
2025;27(9):1113-1118
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To investigate the clinical features and prognosis of children with non-Down-syndrome-related acute megakaryoblastic leukemia (non-DS-AMKL).
METHODS:A retrospective analysis was conducted on the medical data of 17 children with non-DS-AMKL who were admitted to Children's Hospital of The First Affiliated Hospital of Zhengzhou University from January 2013 to December 2023, and their clinical features, treatment, and prognosis were summarized.
RESULTS:Among the 17 children with non-DS-AMKL, there were 8 boys and 9 girls. Fourteen patients had an onset age of less than 36 months, with a median age of 21 months (range:13-145 months). Immunophenotyping results showed that 16 children were positive for CD61 and 13 were positive for CD41. The karyotype analysis was performed on 16 children, with normal karyotype in 6 children and abnormal karyotype in 9 children, among whom 5 had complex karyotype and 1 had no mitotic figure. Detected fusion genes included EVI1, NUP98-KDM5A, KDM5A-MIS18BP1, C22orf34-BRD1, WT1, and MLL-AF9. Genetic alterations included TET2, D7S486 deletion (suggesting 7q-), CSF1R deletion, and PIM1. All 17 children received chemotherapy, among whom 16 (94%) achieved complete remission after one course of induction therapy, and 1 child underwent hematopoietic stem cell transplantation (HSCT) and remained alive and disease-free. Of all children, 7 experienced recurrence, among whom 1 child received HSCT and died of graft-versus-host disease. At the last follow-up, six patients remained alive and disease-free.
CONCLUSIONS:Non-DS-AMKL primarily occurs in children between 1 and 3 years of age. The patients with this disorder have a high incidence rate of chromosomal abnormalities, with complex karyotypes in most patients. Some patients harbor fusion genes or gene mutations. Although the initial remission rate is high, the long-term survival rate remains low.
